497 related articles for article (PubMed ID: 10769676)
1. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer.
Miyake H; Hanada N; Nakamura H; Kagawa S; Fujiwara T; Hara I; Eto H; Gohji K; Arakawa S; Kamidono S; Saya H
Oncogene; 1998 Feb; 16(7):933-43. PubMed ID: 9484785
[TBL] [Abstract][Full Text] [Related]
4. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
5. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
6. The relationship between p53 status and anticancer drugs-induced apoptosis in nine human bladder cancer cell lines.
Chang FL; Lai MD
Anticancer Res; 2000; 20(1A):351-5. PubMed ID: 10769679
[TBL] [Abstract][Full Text] [Related]
7. Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.
Chang FL; Lai MD
J Urol; 2001 Jul; 166(1):304-10. PubMed ID: 11435891
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated and hypoacetylated mutant p53 enhances cisplatin-induced apoptosis through caspase-9 pathway in the absence of transcriptional activation or translation.
Lai MD; Lin WC; Sun YM; Chang FL
Int J Mol Med; 2005 Apr; 15(4):725-34. PubMed ID: 15754039
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene.
Seki T; Ohba N; Makino R; Funatomi H; Mitamura K
Anticancer Res; 2001; 21(3B):1919-24. PubMed ID: 11497278
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
Fan S; el-Deiry WS; Bae I; Freeman J; Jondle D; Bhatia K; Fornace AJ; Magrath I; Kohn KW; O'Connor PM
Cancer Res; 1994 Nov; 54(22):5824-30. PubMed ID: 7954409
[TBL] [Abstract][Full Text] [Related]
13. Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis.
Raffo AJ; Kim AL; Fine RL
Oncogene; 2000 Dec; 19(54):6216-28. PubMed ID: 11175336
[TBL] [Abstract][Full Text] [Related]
14. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
[TBL] [Abstract][Full Text] [Related]
15. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
Eliopoulos AG; Kerr DJ; Herod J; Hodgkins L; Krajewski S; Reed JC; Young LS
Oncogene; 1995 Oct; 11(7):1217-28. PubMed ID: 7478541
[TBL] [Abstract][Full Text] [Related]
16. [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin].
Jin Z; Guan T; Li S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun; 19(3):218-20. PubMed ID: 12048682
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C
Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification.
Gjerset RA; Lebedeva S; Haghighi A; Turla ST; Mercola D
Cell Growth Differ; 1999 Aug; 10(8):545-54. PubMed ID: 10470854
[TBL] [Abstract][Full Text] [Related]
19. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.
Tsuchiya H; Mori Y; Ueda Y; Okada G; Tomita K
Anticancer Res; 2000; 20(1A):235-42. PubMed ID: 10769661
[TBL] [Abstract][Full Text] [Related]
20. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.
Ju JF; Banerjee D; Lenz HJ; Danenberg KD; Schmittgen TC; Spears CP; Schönthal AH; Manno DJ; Hochhauser D; Bertino JR; Danenberg PV
Clin Cancer Res; 1998 May; 4(5):1315-22. PubMed ID: 9607592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
